Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Valbiotis SA (ALVAL) Price & Analysis

ALVAL Stock Chart & Stats

€0.63-€0.02(-3.24%)
At close: 4:00 PM EDT
EUR 0.5EUR 0.6EUR 0.7EUR 0.83 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 0.60 - EUR 0.66
52-Week Range
EUR 0.49 - EUR 1.27
Previous Close
EUR 0.65
Volume
46.37K
Average Volume (3M)
133.57K
Market Cap
EUR 22.31M
Enterprise Value
EUR 12.83M
Total Cash (Recent Filing)
EUR 8.68M
Total Debt (Recent Filing)
EUR 5.09M
Price to Earnings (P/E)
―
Beta
-0.15
Next Earnings
Mar 17, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Nutrition-health Product Focus

Valbiotis operates in the nutrition-health intersection, targeting prevention and support for cardiometabolic conditions. Its focus on plant-based or bioactive formulations and clinical evaluation provides a defined platform for developing products that may address expanding health and prevention needs.

Manageable Leverage

Leverage remains manageable relative to the company’s recent range, which provides some balance-sheet support despite operating losses. This gives Valbiotis more flexibility than a heavily indebted business to pursue development activities and manage financing needs over the next several quarters.

2025 Revenue Rebound

The sharp revenue rebound in 2025 indicates that Valbiotis has demonstrated some ability to generate commercial income after the 2024 decline. If converted into repeatable product sales or partner revenue, this recovery could improve operating leverage and support the company’s development model.

Bears Say

Persistent Unprofitability

The scale of the 2025 net loss relative to revenue shows that Valbiotis remains far from operating profitability. Continued losses can consume capital, constrain investment choices, and make the business dependent on future commercial progress or additional financing to sustain development.

Ongoing Cash Burn

Sustained negative operating and free cash flow means the business is not self-funding its operations. Continued annual cash burn increases reliance on external capital and may limit the company’s ability to finance product development, commercialization, and other strategic priorities independently.

Volatile Revenue And Weak Margins

Material revenue volatility, including a much higher 2023 followed by a 2024 collapse, reduces visibility into the commercial trajectory. Negative gross profit in 2024 and 2025 also shows that current revenue scale is insufficient to absorb costs, challenging margin sustainability.

Valbiotis SA News

ALVAL FAQ

What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.49 and its highest was €1.27 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €22.31M.
When is Valbiotis SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Oct 12, 2026. The company reported -€0.095 earnings per share for the quarter.
Is Valbiotis SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 35,538,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.095 in its last earnings report. Following the earnings report the stock price went up 9.635%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in FR:ALVAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology